Cost of illness for neuromuscular diseases in the United States

Muscle and Nerve

Volumn 49, Issue 3, 2014, Pages 431-438

  Larkindale, Jane ^a   Yang, Wenya ^b   Hogan, Paul F ^b   Simon, Carol J ^c   Zhang, Yiduo ^d   Jain, Anjali ^b   Habeeb Louks, Elizabeth M ^a   Kennedy, Annie ^a   Cwik, Valerie A ^a  

^a Muscular Dystrophy Association   (United States)

^b LEWIN GROUP   (United States)

^c Unitedhealth Center for Health Reform   (United States)

^d MEDIMMUNE   (United States)

Author keywords

Amyotrophic lateral sclerosis; Cost of illness; Duchenne Muscular Dystrophy; Myotonic Dystrophy; Neuromuscular diseases

Indexed keywords

AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; COST OF ILLNESS; DUCHENNE MUSCULAR DYSTROPHY; HEALTH CARE COST; HEALTH INSURANCE; HOUSEHOLD; HUMAN; INCOME; MYOTONIC DYSTROPHY; PREVALENCE; PRIORITY JOURNAL; UNITED STATES;

AMYOTROPHIC LATERAL SCLEROSIS; COST OF ILLNESS; DUCHENNE MUSCULAR DYSTROPHY; MYOTONIC DYSTROPHY; NEUROMUSCULAR DISEASES;

COST OF ILLNESS; DATABASES, FACTUAL; FEMALE; HEALTH CARE COSTS; HEALTH SURVEYS; HUMANS; MALE; MEDICARE; NEUROMUSCULAR DISEASES; UNITED STATES;

EID: 84893960991     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23942     Document Type: Article

References (16)

1. Aboussouan LS, Khan SU, Meeker DP, Stelmach K, Mitsumoto H. Effect of noninvasive positive-pressure ventilation on survival in amyotrophic lateral sclerosis. Annf Intern Med 1997;127:450.
2. Wong BLY, Christopher C. Corticosteroids in Duchenne muscular dystrophy: a reappraisal. J Child Neurol 2002;17:183.
3. Malik V, Rodino-Klapac LR, Mendell JR. Emerging drugs for Duchenne muscular dystrophy. Expert Opin Emerg Drugs 2012;17:261-277.
4. Venkova-Hristova K, Christov A, Kamaluddin Z, Kobalka P, Hensley K. Progress in therapy development for amyotrophic lateral sclerosis. Neurol Res Int 2012;2012:187234.
5. Foff EP, Mahadevan MS. Therapeutics development in myotonic dystrophy type 1. Muscle Nerve 2011;44:160-169.
6. Access Economics.The cost of muscular dystrophy. 2007 Oct 19. http://www.mda.org.au/media/accesslaunch/ExecutiveSummary5.pdf. Accessed on Feb 2010.
7. Ouyang L, Grosse SD, Kenneson A. Health care utilization and expenditures for children and young adults with muscular dystrophy in a privately insured population. J Child Neurol 2008;23:883-888.
8. Schepelmann K, Winter Y, Spottke AE, Claus D, Grothe C, Schroder R, et al. Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy. J Neurol 2010;257:15-23.
9. Van DerSteen I, Van DenBerg JP, Buskens E, Lindeman E, Van DenBerg L. The costs of amyotrophic lateral sclerosis, according to type of care. Amyotroph Lateral Scler 2009;10:27-34.
10. Lopez-Bastida J, Perestelo-Perez L, Monton-Alvarez F, Serrano-Aguilar P, Alfonso-Sanchez JL. Social economic costs and health-related quality of life in patients with amyotrophic lateral sclerosis in Spain. Amyotroph Lateral Scler 2009;10:237-243.
11. Orphanet Report Series. Prevalence of rare diseases: Bibliographic data - May 2012 - Number 1. http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf
12. Wagner L, Archer NP, Williamson DM, Henry JP, Schiffer R, Jackson CE. Prevalence of amyotrophic lateral sclerosis in Texas, 1998-2003. Tex Med 2012;108:e1.
13. Centers for Disease Control and Prevention (CDC). Prevalence of Duchenne/Becker muscular dystrophy among males aged 5-24 years - four states, 2007. MMWR Morb Mortal Wkly Rep 2009;58:1119-1122.
14. Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology 2006;66:1696-1702.
15. Huse DM, Schulman K, Orsini L, Castelli-Haley J, Kennedy S, Lenhart G. Burden of illness in Parkinson's disease. Move Disord 2005;20:1449-1454.
16. O'Brien JA, Ward A, Michels SL, Tzivelekis S, Brandt NJ. Economic burden associated with Parkinson disease. Drug Benefit Trends 2009;21:179-190.